



The Patent Office  
Concept House  
Cardiff Road  
Newport  
South Wales  
NP10 8QQ

I, the undersigned, being an officer duly authorised in accordance with Section 74(1) and (4) of the Deregulation & Contracting Out Act 1994, to sign and issue certificates on behalf of the Comptroller-General, hereby certify that annexed hereto is a true copy of the documents as originally filed in connection with the patent application identified therein.

In accordance with the Patents (Companies Re-registration) Rules 1982, if a company named in this certificate and any accompanying documents has re-registered under the Companies Act 1980 with the same name as that with which it was registered immediately before re-registration save for the substitution as, or inclusion as, the last part of the name of the words "public limited company" or their equivalents in Welsh, references to the name of the company in this certificate and any accompanying documents shall be treated as references to the name with which it is so re-registered.

In accordance with the rules, the words "public limited company" may be replaced by p.l.c., plc, P.L.C. or PLC.

Re-registration under the Companies Act does not constitute a new legal entity but merely subjects the company to certain additional company law rules.

Signed

Dated 11 January 2001



Patents Act 1977  
(Rule 16)


19JAN00 E506234-5 002898  
F01/7700 0.00-0001130.4

The Patent Office

Cardiff Road  
Newport  
Gwent NP10 8QQ

**Request for grant of a patent**

(See the notes on the back of this form. You can also get  
an explanatory leaflet from the Patent Office to help  
you fill in this form)



1. Your reference **J3514(C)/PMK**

2. Patent application number  
(The Patent Office will fill in this part)

18 JAN 2000

0001130.4

3. Full name, address and postcode of the or of  
each applicant (underline all surnames)

**UNILEVER PLC  
UNILEVER HOUSE, BLACKFRIARS  
LONDON, EC4P 4BQ**

Patents ADP number (if you know it)

1628001

If the applicant is a corporate body, give the  
country/state of its incorporation

**UNITED KINGDOM**

4. Title of the invention

**ANTI-MICROBIAL ANTIPERSPIRANT  
PRODUCTS**

5. Name of your agent (if you have one)

**PEARCE, Timothy**

"Address for Service" in the United Kingdom  
to which all correspondence should be sent  
(including the postcode)

**PATENT DEPARTMENT, UNILEVER PLC  
COLWORTH HOUSE, SHARNBROOK  
BEDFORD, MK44 1LQ**

Patents ADP number (if you know it)

766757900

6. If you are declaring priority from one or more  
earlier patent applications, give the country  
and the date of filing of the or of each of these  
earlier applications and (if you know it) the or  
each application number

Country	Priority application number (if you know it)	Date of filing (day / month / year)

7. If this application is divided or otherwise  
derived from an earlier UK application,  
give the number and the filing date of  
the earlier application

Number of earlier application	Date of filing (day/month/year)

8. Is a statement of inventorship and of right  
to grant of a patent required in support of  
this request? (Answer 'Yes' if:

**YES**

- a) any applicant named in part 3 is not an inventor, or
  - b) there is an inventor who is not named as an applicant, or
  - c) any named applicant is a corporate body.
- See note (d))

9. Enter the number of sheets for any of the following items you are filing with this form. Do not count copies of the same document

Continuation sheets of this form

Description	28
Claim(s)	2
Abstract	
Drawing(s)	

10. If you are also filing any of the following, state how many against each item.

Priority Documents

Translations of priority documents

Statement of inventorship and right to grant of a patent (*Patents Form 7/77*)

Request for preliminary examination and search (*Patents Form 9/77*) 1

Request for substantive examination (*Patents Form 10/77*)

Any other documents  
(please specify)

11. I/We request the grant of a patent on the basis of this application.

Signature(s)

Date: 18/01/00

Sandra Jane EDWARDS, Authorised Signatory

12. Name and daytime telephone number of person to contact in the United Kingdom Petra Kimber, Tel 01234 222893

Warning

After an application for a patent has been filed, the Comptroller of the Patent Office will consider whether publication or communication of the invention should be prohibited or restricted under Section 22 of the Patents Act 1977. You will be informed if it is necessary to prohibit or restrict your invention in this way. Furthermore, if you live in the United Kingdom, Section 23 of the Patents Act 1977 stops you from applying for a patent abroad without first getting written permission from the Patent Office unless an application has been filed at least 6 weeks beforehand in the United Kingdom for a patent for the same invention and either no direction prohibiting publication or communication has been given, or any such direction has been revoked.

Notes

- If you need help to fill in this form or you have any questions, please contact the Patent Office on 0645 500505.
- Write your answers in capital letters using black ink or you may type them.
- If there is not enough space for all the relevant details on any part of this form, please continue on a separate sheet of paper and write "see continuation sheet" in the relevant part(s). Any continuation sheet should be attached to this form.
- If you have answered 'Yes' Patents Form 7/77 will need to be filed.
- Once you have filled in the form you must remember to sign and date it.
- For details of the fee and ways to pay please contact the Patent Office.

ANTI-MICROBIAL ANTIPERSPIRANT PRODUCTSField of Invention

5

This invention relates to the field of anti-microbial compositions and to methods of reducing microbial numbers. In particular, this invention is concerned with reducing microbial numbers upon the surface of the human body and thereby reducing body odour. The compositions and methods involved utilise a transition metal chelator together with an antiperspirant active. When used on the human body, the compositions and methods of the invention are of greatest benefit when used on the most malodorous areas of the body, for example the underarm areas or feet.

Background

20 Typically, a deodorising composition will attempt to significantly reduce or prevent body odour by reducing either perspiration or the number of viable micro-organisms on the body surface as represented herein by skin. The former is usually referred to as an antiperspirant composition and the latter a deodorant. Other compositions attempt to mask body malodours using perfumes.

30 Compositions reducing perspiration often comprise a metal salt, such as an aluminium or zirconium salt, which blocks the sweat pores. This method is very simple, yet perspiration is rarely reduced by more than 50%.

Deodorants, on the other hand, reduce the numbers of viable micro-organisms on the body surface such as skin. It is well known that sweat is usually odourless until it has been

35

degraded by the skin microflora. Typical deodorants include ethanol and triclosan (2',4,4'-trichloro,2-hydroxy-diphenyl ether) which is a well known anti-microbial agent. However, the deodorising effect obtained with such deodorants wears  
5 off with the passage of time and the microflora progressively recover their numbers.

There is, therefore, a continuing requirement for effective, long lasting antiperspirant deodorant compositions for the  
10 market. The problem to be solved is not simply reducing sweating and initial microbial numbers on the body surface; equally important is maintaining low microbial numbers (particularly low bacterial numbers) on the body surface (particularly in the most malodorous areas, e.g. the  
15 axilla).

Transition metal chelators have previously been incorporated into antiperspirant deodorant compositions as formulation aids. US 5,516,511 (Procter and Gamble Co.) discloses  
20 particular antiperspirant gel compositions in which chelators are used during manufacture to prevent reaction between the active and the primary gellant, the latter component comprising 12-hydroxystearic acid or a derivative thereof. The chelators disclosed include acetylacetone,  
25 ethylenediaminetetraacetic acid (EDTA), and trans-1,2-diaminocyclohexane-N,N,N',N'-tetraacetic acid (CDTA).

US 5,849,276 (Procter and Gamble Co.) mentions chelators in antiperspirant stick compositions, although such materials  
30 are stated to be optional "non-active" components. EDTA is the only chelator specifically disclosed.

Transition metal chelators have also been disclosed in simple deodorant compositions, that is to say, deodorant

compositions excluding antiperspirant actives. US 4,356,190  
discloses the use of selected aminopolycarboxylic acid  
compounds for inhibiting malodour formation; WO 97/01360  
(Concat Ltd.) claims a method of inhibiting bacterial growth  
5 using particular substituted polyaza compounds that show  
affinity for first transition series elements; WO 97/44006  
(Ciba Speciality Chemicals Holding, Inc.) claims the use of  
nitrogen-containing complexing agents for the anti-microbial  
treatment of the skin and of textile fibre materials; and WO  
10 97/02010 discloses the use of chelators selected from the  
succinic acid, glutaric acid, and phosphonic acid classes as  
bactericidal compounds.

Other patents indicate that transition metal chelators can  
15 improve the efficacy of specific known anti-microbials. WO  
98/12399 (Public Health Research Institute of the City of  
New York) discloses improved performance of lanthionine-  
containing bacteriocins in compositions also comprising a  
transition metal chelator. WO 97/09974 (Laboratoire Medix)  
20 discloses compositions comprising chlorhexidine and a  
chelator. EP 0019670 B1 (Glyco Chemicals, Inc.) discloses  
anti-microbial compositions comprising a condensation  
product of 5,5-dimethyl hydantoin and formaldehyde in  
combination with a water-soluble chelating agent selected  
25 from EDTA, diethylenetriaminepentaacetic acid (DTPA) or the  
alkali metal salts thereof. US 4,199,602 (Economics  
Laboratory, Inc.) discloses the potentiation of anti-  
microbial nitroalkanes by aminocarboxylic-type chelating  
agents. US 5,688,516 (University of Texas System et al)  
30 discloses compositions comprising non-glycopeptide anti-  
microbials (other than vancomycin) in combination with a  
selection of components, including a chelating agent. WO  
99/10017 (University of Texas System et al) discloses a  
method for controlling the growth of micro-organisms using a  
35 chelating agent and an anti-microbial agent. GB 1,420,946

(Beecham Group Ltd.) discloses that the activity of selected phenolic anti-microbials can be vastly increased by certain chelating agents, in particular the disodium salt of EDTA.

5

#### Summary of the Invention

It has been unexpectedly found that the combined use of an antiperspirant active and a micromolar-active transition  
10 metal chelator can lead to a surprisingly good and long-lasting anti-microbial benefit.

Herein, 'micromolar-active' refers to the ability of a material to significantly inhibit the growth of a relevant  
15 micro-organism when present, in a medium containing said micro-organism, at a concentration of  $3 \times 10^{-6}$  mol.dm<sup>-3</sup> or less. Inhibition is considered significant when growth of the relevant micro-organism on a supporting medium can be reduced by at least 30%, preferably by at least 45%.

20

Thus, according to a first aspect of the present invention, there is provided an anti-microbial product comprising an antiperspirant active and a micromolar-active transition metal chelator.

25

According to a second aspect of the present invention, there is provided a method of controlling microbial numbers, said method comprising the application to a substrate of an antiperspirant active and a micromolar-active transition  
30 metal chelator. A particular application of this aspect of the invention is the control of microbial numbers on the surface of the human body, and the resulting control of body odour, for example lasting as long as a day. This particular application also provides a method for reducing



perspiration and providing additional control of bacterial numbers on the skin surface.

According to a third aspect of the present invention, there is provided a method for the manufacture of an anti-microbial composition comprising the mixing of an antiperspirant active with a micromolar-active transition metal chelator.

10

#### Detailed Description

The antiperspirant active and the micromolar-active transition metal chelator both function as effective anti-microbial agents in this invention. On application to the human body, the reduced perspiration benefit delivered by the antiperspirant active is also beneficial and further contributes to the deodorancy benefit resulting from the anti-microbial performance of the components of the product. Without wishing to be bound by theory, it is hypothesised that after reduction of microbial numbers by the antiperspirant active, the transition metal chelator effectively inhibits the up-take of essential transition metal ion nutrients by the remaining microbes, thereby minimising their re-growth. Surprisingly, no detrimental interaction between the antiperspirant active and the transition metal chelator affects the overall anti-microbial and deodorancy benefit of the products of the invention.

It is not essential that the antiperspirant active and the chelator are part of the same composition. The anti-microbial benefit derived from use of the invention may be gained by independent application of the antiperspirant active and the chelator. Such application may be concurrent

or consecutive, provided that the treated substrate experiences the presence of both components at the same time. When the components are applied from independent compositions, it is preferred that the product also  
5 comprises a means for, and/or instruction for, both of the compositions to be applied to the substrate requiring treatment.

It is preferred that the anti-microbial product of the  
10 invention comprises an antiperspirant active and a micromolar-active transition metal chelator that are both present in the same composition. The benefits found with such compositions can include good product aesthetics, lack of product separation, attainment of the desired rheology,  
15 visco-stability, good dispensing, and any combination of these benefits or others.

The method of controlling microbial numbers offered by the invention is particularly useful because the benefit can  
20 extend for many hours, for example 5 hours, or 24 hours, or even longer, after application of the product to the substrate. When the substrate is the skin of the human body, this can result in an extended deodorancy benefit; that is to say, extended inhibition of generation of human  
25 body odour.

The antiperspirant active and the chelator may be present in the composition or compositions of the invention in any form. For example, either or both of the agents may be used  
30 neat or may be diluted with a volatile propellant and used as an aerosol; with an additional liquid and used, for example, as a roll-on or squeeze-spray product; or with a thickener or structurant and used; for example, as a cream, gel or solid stick product.

The anti-microbial product of the invention may be applied to the substrate requiring treatment by any means. Frequently, the substrate requiring treatment is a surface. Application of liquid compositions can be by absorption onto  
5 a carrier matrix like paper, fabric, or sponge and application by contacting said carrier matrix with the surface. Solid or semi-solid compositions can be applied by direct contact or can be dissolved or dispersed in a liquid medium prior to application. Application can also comprise  
10 a combination of any two or more of the above techniques.

### Chelators

15 The anti-microbial efficacy at low concentration is the key attribute of the transition metal chelators of the invention. As stated above, the chelators are required to be 'micromolar-active' against a relevant micro-organism. The 'relevant micro-organism' should be representative of  
20 those associated with the substrate to be treated. When the substrate to be treated is human skin, a relevant micro-organism is Staphylococcus epidermidis. Other relevant micro-organisms include Coryneform spp., Salmonella spp., Escherichia Coli, and Pseudomonas spp., in particular P.  
25 aeruginosa. Micromolar-active transition metal chelators include DTPA and triethylenetetraaminehexaacetic acid (TTHA), but exclude EDTA and CDTA.

Preferred micromolar-active transition metal chelators have  
30 affinity for iron (III), preferably high affinity for iron (III); that is to say, a binding constant for iron (III) of greater than  $10^{10}$ , or, for optimum performance, greater than  $10^{26}$ . The 'iron (III) binding constant' referred to above is the absolute stability constant for the chelator-iron (III)  
35 complex. Such values are independent of pH and are measured

on the most anionic, fully deprotonated form of the chelator. Measurements can be made potentiometrically, and in a number of other ways. Full details of suitable methods can be found in "Determination and Use of Stability

5 Constants", A. E. Martell and R. J. Motekaitis (VCH, New York, 1989). Tables of such values may be found in numerous sources, for example "Critical Stability Constants", R. M. Smith and A. E. Martell (Plenum Pub. Corp., 1977).

10

The micro-molar active chelator may be used in its acid form, but it may also be used as one of its salts.

15

Preferably the chelators used in the present invention have acid forms with at least two ionisable acid groups. The acid groups are preferably carboxylic and/or phosphonic, but may be sulphonic or phosphinic, or any mixture of these groups.

20

Particularly suitable chelators for use include polycarboxylate compounds, in particular aminopolycarboxylate compounds. The acid forms of the aminopolycarboxylate compounds include DTPA and TTHA, as already mentioned.

25

The chelators or salts thereof preferably have only moderate molecular weight, by which it is meant that the chelators, in their acid forms, have a molecular weight of less than 1000, more preferably 200 to 800, and most preferably 290 to 580, and in their salt form have a molecular weight of less

30

than 2000, more preferably 300 to 1400, and most preferably 500 to 1000.

The chelator is preferably incorporated into a composition at a level of 0.01% to 10%, more preferably at a level of

0.05% to 5%, and most preferably at a level 0.3% to 3% by weight of the non-volatile components of the composition. Mixtures of chelator salts may also be used.

Herein, non-volatile components are those having a boiling point greater than 20°C at atmospheric pressure.

As already mentioned, the chelator may be used in its acid form or as one of its salts. Preferred salts, for certain applications, are monovalent alkali metal salts such as sodium and potassium salts. For certain other applications, for example formulation in alcohol-based compositions, salts with organic counter-ions are preferred, for example protonated or quaternised amines. Salts formed using aliphatic amines are generally preferred to those formed from aromatic amines. A further preference is for protonated or quaternised amine cations possessing a C<sub>1</sub>-C<sub>10</sub> terminal hydrocarbyl group, wherein a hydrocarbyl group is a radical comprising solely carbon and hydrogen atoms. Such relatively hydrophobic organic counter-ions lead to particularly good compatibility between the chelator salt and the organic anti-microbial.

Preferred protonated or quaternised amine cations of the chelator salts are of formula R<sup>1</sup>R<sup>2</sup>R<sup>3</sup>R<sup>4</sup>N<sup>(+)</sup>, wherein R<sup>1</sup> is H or CH<sub>3</sub>; R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are each independently H or an aliphatic or aromatic substituent containing 0 to 3 hydroxyl groups, optionally interrupted and/or substituted by functional groups such as ether, amine, ester, or amide; with the provisos that at least one of R<sup>2</sup>, R<sup>3</sup>, or R<sup>4</sup> comprises a C<sub>1</sub>-C<sub>10</sub> terminal hydrocarbyl group, optionally R<sup>2</sup> and R<sup>3</sup> together forming a ring as the terminal hydrocarbyl group, and that R<sup>2</sup>, R<sup>3</sup>, and R<sup>4</sup> are not all CH<sub>2</sub>CH(OH)CH<sub>3</sub> groups.

- 10 -

Particularly preferred chelator-amine salts are salts of 2-amino-2-methyl-1-propanol, cyclohexylamine, diisopropanolamine, or 2-amino-1-butanol.

- 5 Partial salts of chelator acids possessing more than one acidic group may also be employed; such salts retain one or more non-ionised acid groups. Also claimed are salts where the cations are in part protonated or quaternised amines and in part some other cation, for example an alkali metal  
10 cation, in particular a sodium ion.

#### Antiperspirant Actives

- 15 Antiperspirant actives are preferably incorporated into a composition in an amount of from 0.5-60%, particularly from 5 to 30% or 40% and especially from 5 or 10% to 30 or 35% of the weight of the composition. The ratio of micro-molar active chelator and/or salt thereof to antiperspirant active  
20 is preferably 1:5 to 1:25 by weight.

- Antiperspirant actives for use herein are often selected from astringent active salts, including in particular aluminium, zirconium and mixed aluminium/zirconium salts,  
25 including both inorganic salts, salts with organic anions and complexes. Preferred astringent salts include aluminium, zirconium and aluminium/zirconium halides and halohydrate salts, such as chlorohydrates.

- 30 Aluminium halohydrates are usually defined by the general formula  $Al_2(OH)_xQ_y \cdot wH_2O$  in which Q represents chlorine, bromine or iodine, x is variable from 2 to 5 and  $x + y = 6$  while  $wH_2O$  represents a variable amount of hydration. Especially effective aluminium halohydrate salts, known as  
35 activated aluminium chlorohydrates, are described in EP

006,739 (Unilever PLC and NV). Some activated salts do not retain their enhanced activity in the presence of water but are useful in substantially anhydrous formulations, i.e. formulations that do not contain a distinct aqueous phase.

5

Zirconium actives can usually be represented by the empirical general formula:  $ZrO(OH)_{2-n-nz}B_n \cdot wH_2O$  in which  $z$  is a variable in the range of from 0.9 to 2.0 so that the value  $2n-nz$  is zero or positive,  $n$  is the valency of  $B$ , and  $B$  is  
10 selected from the group consisting of chloride, other halide, sulphamate, sulphate and mixtures thereof. Possible hydration to a variable extent is represented by  $wH_2O$ . Preferable is that  $B$  represents chloride and the variable  $z$  lies in the range from 1.5 to 1.87. In practice, such  
15 zirconium salts are usually not employed by themselves, but as a component of a combined aluminium and zirconium-based antiperspirant.

The above aluminium and zirconium salts may have coordinated  
20 and/or bound water in various quantities and/or may be present as polymeric species, mixtures or complexes. In particular, zirconium hydroxy salts often represent a range of salts having various amounts of the hydroxy group. Zirconium aluminium chlorohydrate may be particularly  
25 preferred.

Antiperspirant complexes based on the above-mentioned astringent aluminium and/or zirconium salts can be employed. The complex often employs a compound with a carboxylate  
30 group, and advantageously this is an amino acid. Examples of suitable amino acids include dl-tryptophan, dl- $\beta$ -phenylalanine, dl-valine, dl-methionine and  $\beta$ -alanine, and preferably glycine which has the formula  $CH_2CH(NH_2)COOH$ .

It is highly desirable to employ complexes of a combination of aluminium halohydrates and zirconium chlorohydrates together with amino acids such as glycine, which are disclosed in US 3,792,068 (Procter and Gamble Co.). Certain  
5 of those Al/Zr complexes are commonly called ZAG in the literature. ZAG actives generally contain aluminium, zirconium and chloride with an Al/Zr ratio in a range from 2 to 10, especially 2 to 6, an Al/Cl ratio from 2.1 to 0.9 and a variable amount of glycine. Actives of this preferred  
10 type are available from Westwood, from Summit and from Reheis.

Other actives that may be utilised include astringent titanium salts, for example those described in GB 2,299,506.

15 The proportion of solid antiperspirant salt in a composition normally includes the weight of any water of hydration and any complexing agent that may also be present in the solid active. However, when the active salt is in solution, its  
20 weight excludes any water present.

If the composition is in the form of an emulsion the antiperspirant active will be dissolved in the disperse phase. In this case, the antiperspirant active will often  
25 provide from 3 to 60% by weight of the aqueous disperse phase, particularly from 10% or 20% up to 55% or 60% of that phase.

Alternatively, the composition may take the form of a  
30 suspension in which antiperspirant active in particulate form is suspended in the water-immiscible liquid carrier. Such a composition will probably not have any separate aqueous phase present and may conveniently be referred to as "substantially anhydrous" although it should be understood  
35 that some water may be present bound to the antiperspirant



active or as a small amount of solute within the water-immiscible liquid phase. In such compositions, the particle size of the antiperspirant salts often falls within the range of 0.1 to 200  $\mu\text{m}$  with a mean particle size often from 3 to 20  $\mu\text{m}$ . Both larger and smaller mean particle sizes can also be contemplated such as from 20 to 50  $\mu\text{m}$  or 0.1 to 1  $\mu\text{m}$ .

#### Additional Components

10 An additional component that can sometimes augment the efficacy of the composition is a further organic anti-microbial agent. Most of the classes of agents commonly used in the art can be incorporated into compositions of the invention. Levels of incorporation are preferably from 15 0.01% to 3%, more preferably from 0.03% to 0.5%. Preferred organic anti-microbial agents have a minimum inhibitory concentration (MIC) of 1  $\text{mg.ml}^{-1}$  or less, particularly 200  $\mu\text{g.ml}^{-1}$  or less, and especially 100  $\mu\text{g.ml}^{-1}$  or less. The MIC of an anti-microbial agent is the minimum concentration of 20 the agent required to significantly inhibit microbial growth. Inhibition is considered "significant" if an 80% or greater reduction in the growth of an inoculum of a relevant micro-organism is observed, relative to a control medium without an anti-microbial agent, over a period of 16 to 24 25 hours at 37°C. The "relevant micro-organism" used for testing should be representative of those associated with the substrate to be treated. When the substrate to be treated is human skin, a relevant micro-organism is *Staphylococcus epidermidis*. Other relevant micro-organisms include 30 *Coryneform* spp. and *Pseudomonas* spp., in particular *P. aeruginosa*. Details of suitable methods for determining MICs can be found in "Antimicrobial Agents and Susceptibility Testing", C.Thornsberry, (in "Manual of Clinical

Microbiology", 5<sup>th</sup> Edition, Ed. A. Balows et al, American Society for Microbiology, Washington D.C., 1991). A particularly suitable method is the Macrobrotth Dilution Method as described in Chapter 110 of above publication (pp. 1101-1111) by D. F. Sahm and J. A. Washington II. MICs of anti-microbials suitable for inclusion in the compositions of the invention are triclosan: 0.01-10  $\mu\text{g}.\text{ml}^{-1}$  (J.Regos et al., Dermatologica (1979), 158: 72-79) and farnesol: ca. 25  $\mu\text{g}.\text{ml}^{-1}$  (K. Sawano, T. Sato, and R. Hattori, Proceedings of the 17<sup>th</sup> IFSCC International Conference, Yokahama (1992) p.210-232). By contrast ethanol and similar alkanols have MICs of greater than 1  $\text{mg}.\text{ml}^{-1}$ . Preferred additional organic anti-microbials are bactericides, for example quaternary ammonium compounds, like cetyltrimethylammonium salts; chlorhexidine and salts thereof; and diglycerol monocaprato, diglycerol monolaurate, glycerol monolaurate, and similar materials, as described in "Deodorant Ingredients", S.A.Makin and M.R.Lowry, in "Antiperspirants and Deodorants", Ed. K. Laden (1999, Marcel Dekker, New York). More preferred anti-microbials for use in the compositions of the invention are polyhexamethylene biguanide salts (also known as polyaminopropyl biguanide salts), an example being Cosmocil CQ<sup>TM</sup> available from Zeneca PLC, preferably used at up to 1% and more preferably at 0.03% to 0.3% by weight; 2',4,4'-trichloro,2-hydroxy-diphenyl ether (triclosan), preferably used at up to 1% by weight of the composition and more preferably at 0.05-0.3%; and 3,7,11-trimethyldodeca-2,6,10-trienol (farnesol), preferably used at up to 1% by weight of the composition and more preferably at up to 0.5%.

A carrier fluid is a highly desirable additional component of the compositions of the invention. Such materials act as solvents or carriers for the other components of the composition, facilitating their delivery. Water can be used

as a carrier fluid, although it is more preferable to use mixtures of water and an alcohol such as C2 to C4 aliphatic alcohol, especially ethanol. Alcohol/water mixtures are particularly suitable carrier fluids in roll-on and pump spray products. Cyclomethicones and other volatile silicones are another class of carrier fluid that may be employed. Propylene glycol, butylene glycol, and related glycols may also be used. Other alternative carrier fluids include materials having multiple functions, for example isopropyl myristate, isopropyl palmitate, dipropylene glycol, and glycerol. Mixtures of carrier fluids may also be employed to advantage. Compositions preferably comprise carrier fluid at a level of from 30% to 98% by weight, or more preferably from 60% to 97% by weight, of the non-volatile components of the composition.

Structurants and emulsifiers are further additional components of the compositions of the invention that are highly desirable in certain product forms. Structurants, when employed, are preferably present at from 1% to 30% by weight of the composition, whilst emulsifiers are preferably present at from 0.1% to 10% by weight of the composition. In roll-ons, such materials help control the rate at which product is dispensed by the roll ball. In stick compositions, such materials can form gels or solids from solutions or suspensions of the chelator salt in a carrier fluid. Suitable structurants for use in such compositions of the invention include cellulosic thickeners such as hydroxy propyl cellulose and hydroxy ethyl cellulose, 12-hydroxystearic acid, esters of 12-hydroxystearic acid, amides of 12-hydroxystearic acid, N-lauroyl-glutamic acid dibutyl amide, 2-dodecyl-N,N'-dibutyl-succinamide, and dibenzylidene sorbitol. Emulsion pump sprays, roll-ons, creams, and gel compositions according to the invention can be formed using a range of oils, waxes, and emulsifiers.

Suitable emulsifiers include steareth-2, steareth-20, steareth-21, cetareth-20, glyceryl stearate, cetyl alcohol, cetearyl alcohol, PEG-20 stearate, and dimethicone copolyol. Suspension aerosols, roll-ons, sticks, and creams require  
5 structurants to slow sedimentation (in fluid compositions) and to give the desired product consistency to non-fluid compositions. Suitable structurants include sodium stearate, stearyl alcohol, cetyl alcohol, hydrogenated  
10 castor oil, synthetic waxes, paraffin waxes, hydroxystearic acid, dibutyl lauroyl glutamide, alkyl silicone waxes, quaternium-18 bentonite, quaternium-18 hectorite, silica, and propylene carbonate. Some of the above materials also function as suspending agents in certain compositions.

15 Further emulsifiers desirable in certain compositions of the invention are perfume solubilisers and wash-off agents. Examples of the former include PEG-hydrogenated castor oil, available from BASF in the Cremaphor RH and CO ranges, preferably present at up to 1.5% by weight, more preferably  
20 0.3 to 0.7% by weight. Examples of the latter include poly(oxyethylene) ethers.

Certain sensory modifiers are further desirable components in the compositions of the invention. Such materials are  
25 preferably used at a level of up to 20% by weight of the composition. Emollients, humectants, volatile oils, non-volatile oils, and particulate solids which impart lubricity are all suitable classes of sensory modifiers. Examples of such materials include cyclomethicone, dimethicone,  
30 dimethiconol, isopropyl myristate, isopropyl palmitate, talc, finely-divided silica (e.g. Aerosil 200), polyethylene (e.g. Acumist B18), polysaccharides, corn starch, C12-C15 alcohol benzoate, PPG-3 myristyl ether, octyl dodecanol, C7-C14 isoparaffins, di-isopropyl adipate, isosorbide laurate,  
35 PPG-14 butyl ether, glycerol, hydrogenated polyisobutene,

polydecene, titanium dioxide, phenyl trimethicone, dioctyl adipate, and hexamethyl disiloxane.

5      Fragrance is also a desirable additional component in the compositions of the invention. Suitable materials include conventional perfumes, such as perfume oils and also include so-called deo-perfumes, as described in EP 545,556 and other publications. Levels of incorporation are preferably up to 4% by weight, particularly from 0.1% to 2% by weight, and  
10     especially from 0.7% to 1.7% by weight.

It should be noted that certain components of compositions perform more than one function. Such components are particularly preferred additional ingredients, their use  
15     often saving both money and formulation space. Examples of such components include ethanol, isopropyl myristate, and the many components that can act as both structurants and sensory modifiers, for example silica.

20     Further additional components that may also be included are colourants and preservatives, for example C<sub>1</sub>-C<sub>8</sub> alkyl parabens.

## 25     Product Forms

The compositions of the invention may take any form. Examples include wax-based sticks, soap-based sticks, compressed powder sticks, roll-on suspensions or solutions,  
30     emulsions, gels, creams, squeeze sprays, pump sprays, and aerosols. Each product form contains its own selection of additional components, some essential and some optional. The types of components typical for each of the above product forms may be incorporated in the corresponding  
35     compositions of the invention.

The various product forms of the invention each can have additional components that are desirably present. Roll-on compositions of the invention preferably have a low level of non-volatile emollient present, for example isopropyl myristate or propylene glycol at 0.2-2% by weight. Antiperspirant sticks have cyclomethicone as the most preferred carrier fluid. Also preferably present are one or more ethers or esters previously mentioned as sensory modifiers; these materials can serve to mask deposits. Wash-off agents are also desirable in such compositions. Further details of preferred additional components may be found earlier in the specification.

#### Aerosol Compositions

Aerosol compositions of the invention are a particularly preferred product form. Preferably the propellant is the major component in such compositions, comprising from 30 to 99 parts by weight, more preferably from 50 to 95 parts by weight.

The propellant is normally selected from liquified hydrocarbons or halogenated hydrocarbon gases (particularly fluorinated hydrocarbons such as 1,1-difluoroethane and/or 1-trifluoro-2-fluoroethane) that have a boiling point of below 10°C and especially those with a boiling point below 0°C. It is especially preferred to employ liquified hydrocarbon gases, and especially C<sub>3</sub> to C<sub>5</sub> hydrocarbons, including propane, isopropane, butane, isobutane, pentane and isopentane and mixtures of two or more thereof. Preferred propellants are isobutane, isobutane/isopropane, isobutane/propane and mixtures of isopropane, isobutane and butane.

Other propellants that can be contemplated include alkyl ethers, such as dimethyl ether or compressed non-reactive gasses such air, nitrogen or carbon dioxide.

5 The base composition, which is mixed with the propellant, may comprise any of the following components as preferred additional ingredients: a carrier fluid, a fragrance, an emollient (e.g. isopropyl myristate or propylene glycol) or  
10 an anticlogging agent (in order to prevent or minimise the occurrence of solid occlusions in the spray nozzle). Further components may be added to mask powdery deposits, for example non-volatile oils, long chain alcohols (e.g. octyl dodecanol), ethers (e.g. PPG-14 butyl ether), or dimethicone fluids.

15 The aerosol composition is usually filled into an aerosol canister that is capable of withstanding pressures generated by the formulation, employing conventional filling apparatus and conditions. The canister can conveniently be a metal  
20 canister commercially available fitted with a dip tube, valve and spray nozzle through which the formulation is dispensed.

## 25 Methods of Manufacture

The details of the relevant methods of manufacture depend upon the product form concerned. For compositions comprising both an antiperspirant active and a micromolar-  
30 active transition metal chelator, the basic method comprises the mixing of these two components. Further details may be found with the Examples.

## Examples

35 (Note that "letter" codes refer to Comparative Examples.)

Preparation of Aerosol Antiperspirant Deodorants

Example 1 (see Table 1B) was prepared in the following manner. 0.54 g of quaternium-18-hectorite was gradually  
5 added to 5.50 g of volatile silicone fluid (DC 245, ex. Dow Corning), whilst shearing at a speed of ca. 8000 rpm on a Silverson L4RT mixer (ex. Silverson, Chesham, Bucks.). After approximately 10 minutes, 0.18 g of propylene carbonate was added dropwise to the mixture. After a  
10 further 5 minutes of mixing at 8000 rpm, the mixture was removed from the mixer and 0.89 g of DTPA was slowly stirred in. The resulting liquid was mixed for a further 5 minutes and then sealed into a tin plate can, having valve access, and 77.66 g of liquefied propellant (CAP 40, ex Calor) was  
15 introduced into the can from a propellant 'transfer can', via the valve, using a polyethylene transfer device. Finally, the can was fitted with a suitable actuator to enable effective spray application of the product.

20 Example 2 (see Table 1B) was prepared in a similar manner to Example 1, with the addition of poly(hexamethylenebiguanide) stearate (PHMBS, as described in WO98/56252 [Unilever PLC and NV]) (previously passed through a 45 um sieve) at the same time as the DTPA.

25 Comparative Examples A, B, and C (see Tables 1A and 1B) were prepared in a similar manner to Examples 1 and 2, varying the compositions as indicated.



Deodorancy Tests

The deodorancy performance of the compositions detailed below were assessed using the following protocol:

5 A panel was employed comprising 50 individuals who had been instructed to use control ethanolic deodorant products during the week prior to the test. At the start of the test, panellists were washed with unfragranced soap and test  
10 product (1.8 g total weight) applied to one axilla and control product applied to the other (1.8g total weight). (Product application was randomised to take into account any left/right bias). Panellists were instructed not to consume  
15 spicy food or alcohol, and not to wash under their own axillae, during the duration of the test. A minimum of three expert assessors determined the intensity of axillary odour at 5 hours and 24 hours after application, scoring the intensity on a scale of 1-5. After each 24 hour assessment, the panellists were re-washed, and products re-applied, as  
20 above. The procedure was repeated 4 times. At the end of the test the data were analysed using standard statistical techniques. The compositions tested and the mean malodour scores observed are detailed in the following Tables.

Table 1A: Antiperspirant vs. Antiperspirant + PHMBS<sup>1</sup>

Component		Example A	Example B
AACH <sup>2</sup>		5	5
DC245 <sup>3</sup>		7.3	7.257
Bentone 38V <sup>4</sup>		0.5	0.5
Propylene carbonate <sup>5</sup>		0.2	0.2
PHMBS <sup>1</sup>		0	0.043
CAP40 <sup>6</sup>		87	87
Mean malodour intensity <sup>7</sup>	5 hour	1.83	1.91
	24 hour	1.89	1.96

5 All components are expressed as weight per cent of the total composition.

1. Poly(hexamethylenebiguanide) stearate.
2. Activated aluminium chlorohydrate, type A296, ex. Guilini.
- 10 3. Volatile silicone, ex. Dow Corning.
4. Structurant, quaternium-18-hectorite, ex. Rheox.
5. Co-structurant.
6. Propellant, proprietary mix of butane, isobutane and propane, Ex. Calor.
- 15 7. Differences in values not significant at the 95% level.  
(Minimum differences required for significance at the 95% and 99% confidence levels were:  
after 5 hours: 0.09 for 95% level; 0.12 for 99% level;  
after 24 hours: 0.10 for 95% level; 0.13 for 99% level.)

The results in Table 1A indicate that the addition of 0.043% PHMBS anti-microbial to 5% AACH antiperspirant does not lead to an improvement in the deodorancy performance.

5

Table 1B: Effect of Added Chelator

Component		Example C	Example 1	Example 2
AACH		5	5	5
DC245		7.2	6.2	6.16
Bentone 38V		0.6	0.6	0.6
Propylene carbonate		0.2	0.2	0.2
DTPA <sup>1</sup>		0	1.0	1.0
PHMBS		0	0	0.043
CAP40		87	87	87
Mean malodour intensity <sup>2</sup>	5 hour	1.84	1.73	1.67
	24 hour	2.05	1.90	1.88

All components are expressed as weight per cent of the total composition.

1. Diethylenetriaminepentaacetic acid.
2. The difference in mean malodour intensities between examples C and 2 was significant at the 99% level after 5 hours. After 24 hours, the differences between C and 1 and between C and 2 were both significant at the 99% level. (Minimum differences required for significance at the 95% and 99% confidence levels were:  
after 5 hours: 0.12 for 95% level; 0.16 for 99% level;  
after 24 hours: 0.12 for 95% level; 0.15 for 99% level.)

The results in Table 2B indicate that the addition of 1% DTPA chelator to 5% AACH antiperspirant leads to a significant improvement in the deodorancy performance. In the presence of 0.043% additional anti-microbial (PHMBS) the difference is significant after 5 hours, as well as after 24 hours. These latter results are in marked contrast to the effect of added PHMBS in the absence of chelator (Table 1A), where no benefit is observed.

10 The benefits observed after 24 hours indicate that prolonged maintenance of malodour reduction results from the use of the compositions of the invention; this is a direct result of the prolonged anti-microbial activity of the compositions.

15

#### Anti-microbial Performance Tests

The following test demonstrates the micromolar-active nature of DTPA and TTHA.

An axillary isolate of *Staphylococcus epidermidis* was grown overnight in 100 ml of tryptone soy broth (TSB, Oxoid Ltd). 10 ml of this culture was taken and subjected to centrifugation. The separated cells were re-suspended in 10 ml of phosphate buffered saline and the centrifugation procedure repeated. The washed cells were re-suspended in 10 ml of phosphate buffered saline to give the inoculum. 100  $\mu$ l of the inoculum was added to 100 ml of semi-synthetic medium (SSM) containing  $(\text{NH}_4)_2\text{SO}_4$  (0.066 g),  $\text{MgSO}_4 \cdot 7\text{H}_2\text{O}$  (0.012 g), KCl (0.1 g),  $\text{KH}_2\text{PO}_4$  (0.27 g),  $\text{Na}_2\text{HPO}_4$  (1.43 g), thiamin (0.1 mg), biotin (0.05 mg), Peptone P (0.05 g), and glucose (2.0 mmole) which had been previously sterilised by

autoclaving at 121°C for 20 minutes. The pH of the SSM was adjusted to 6.7 with HCl after sterilisation, prior to addition of the inoculum. This control medium was utilised in all of the *in vitro* inhibition studies. The chelator-  
 5 containing test media were prepared in a similar manner, the chelator being introduced at a concentration of  $3 \times 10^{-6}$  mol.dm<sup>-3</sup> before the pH adjustment with HCl.

100 µl of the *S. epidermidis* inoculum was introduced into  
 10 the control medium and into test media containing the chelators indicated in Table 2. The cultures were inoculated at 37°C (with agitation at 200 rpm) for 16 hours, and the optical density of the cultures measured at 600 nm to determine the extent of bacterial growth. By comparison  
 15 of the optical density of the culture in the presence of chelating agent, to that of the control, the percentage inhibition of growth was established. (Optical density measurements were made on 1 in 4 dilutions of the cultures with 0.9% (w/v) saline, using 1 cm path length cuvettes, on  
 20 a Pharmacia Biotech Ultrospec 200 Spectrophotometer.)

Table 2: Results of Anti-microbial Performance Tests

Chelator	Inhibition of growth (%)
EDTA	12.3
CDTA	0
DTPA	56.5
TTHA	56.3

5

Solid and Soft Solid/Cream Compositions

The compositions of Table 3 represent solid and soft solid or cream compositions that may be made in accordance with the invention. Examples 3 and 4 may be made by following the methods described in EP 639,968 (Procter and Gamble Co.) with the modification of adding DTPA acid, or DTPA acid and AMP amine, to the hot melt before cooling. Example 5 may be prepared by following the method described in US 5,718,890 (Procter and Gamble Co.) with the modification of adding DTPA acid and AMP amine to the composition whilst still hot and mobile.

Table 3: Solid and Soft Solid/Cream Compositions

Component	Example 3	Example 4	Example 5
Dibutyl lauroyl glutamide <sup>1</sup>	8	5	0
12-hydroxystearic acid	0	5	0
Light mineral oil <sup>2</sup>	15	0	0
Cyclomethicone <sup>3</sup>	0	39	62
Isopropyl myristate	0	15	0
Polyisobutene <sup>4</sup>	0	15	0
Butyl stearate	0	0	5
Glyceryl tribehenate	0	0	4.8
C <sub>12</sub> -C <sub>15</sub> alkyl benzoate <sup>5</sup>	0	0	0
C <sub>12</sub> -C <sub>16</sub> triglyceride mix <sup>6</sup>	61	0	1.2
Perfume	0	0	0.5
ZAG complex <sup>7</sup>	15	19	25
DTPA	1	1	0
DTPA-AMP salt <sup>8</sup>	0	1	1.5

Figures given are weight per cent of the total composition.

5

1. GP-1, ex Ajinomoto Inc.

2. Benol White Mineral Oil, ex Witco Chem. Co.

3. Dow Corning 245 Fluid for Examples 3 and 4; a cyclic polydimethylsiloxane containing 5 carbon atoms, supplied by GE Silicones, for Example 5.

10

4. Panalane-1-14E, ex Amoco Chem. Co.

5. Finsolv TN, ex Finetex.

6. Ex Westwood Chem. Co.

7. Aluminium zirconium trichlorohydrate gly, ex Westwood Chem. Co.
8. Tri-AMP salt. Prepared *in situ*.



Claims

1. An anti-microbial product comprising an antiperspirant active and a micromolar-active transition metal  
5 chelator.
2. An anti-microbial product according to claim 1,  
characterised in that the antiperspirant active and the  
micromolar-active transition metal chelator are both  
10 present in the same composition.
3. An anti-microbial product according to claim 1 or 2,  
wherein the antiperspirant active is an aluminium, zinc,  
or zirconium astringent salt.  
15
4. An anti-microbial product according to any preceding  
claim, wherein the transition metal chelator has a  
binding constant for iron (III) of greater than  $10^{26}$ .
- 20 5. An anti-microbial product according to any preceding  
claim, wherein the transition metal chelator is a  
polyaminocarboxylic acid or salt thereof.
6. An anti-microbial product according to any preceding  
25 claim, also comprising an additional organic anti-  
microbial agent.
7. An anti-microbial product according to any preceding  
claim, also comprising a carrier fluid.  
30
8. A method of controlling microbial numbers, said method  
comprising the application to a substrate of a product  
according to any of the preceding claims.

9. A cosmetic method of reducing perspiration and providing additional control of bacterial numbers on the human body surface, said method comprising the topical application to the human body of any of the products according to any of claims 1 to 7.

10. A cosmetic method according to claim 9, resulting in reduced body odour.

10 11. A method for the manufacture of an anti-microbial composition comprising mixing an antiperspirant active with a micromolar-active transition metal chelator.